Safety, Pharmacokinetics, and Efficacy of Olorinab, a Peripherally Acting, Highly Selective, Full Agonist of the Cannabinoid Receptor 2, in a Phase 2a Study of Patients With Chronic Abdominal Pain Associated With Crohn's Disease.

Yacyshyn, Bruce R; Hanauer, Stephen; Klassen, Preston; English, Brett A; Stauber, Kathe; Barish, Charles F; Gilder, Kye; Turner, Stewart; Higgins, Peter D R

Yacyshyn, Bruce R; Hanauer, Stephen; Klassen, Preston; English, Brett A; Stauber, Kathe; Barish, Charles F; Gilder, Kye; Turner, Stewart; Higgins, Peter D R.

Afiliação

Yacyshyn BR; Department of Gastroenterology, University of Cincinnati, Cincinnati, Ohio, USA.
Hanauer S; Department of Gastroenterology and Hepatology, Northwestern University, Chicago, Illinois, USA.
Klassen P; Arena Pharmaceuticals Inc., Research and Development, San Diego, California, USA.
English BA; Arena Pharmaceuticals Inc., Clinical Development, San Diego, California, USA.
Stauber K; Arena Pharmaceuticals Inc., Nonclinical Development and Clinical Pharmacology, San Diego, California, USA.
Barish CF; Department of Gastroenterology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
Gilder K; Arena Pharmaceuticals Inc., Biostatistics and Data Management, San Diego, California, USA.
Turner S; Arena Pharmaceuticals Inc., Olorinab Global Program Lead, San Diego, California, USA.
Higgins PDR; Department of Gastroenterology, University of Michigan, Ann Arbor, Michigan, USA.

Crohns Colitis 360 ; 3(1): otaa089, 2021 Jan.

Article em En | MEDLINE | ID: mdl-36777064

Palavras-chave

CB2 agonist; Crohn's disease; cannabinoid; olorinab; pain

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Risk_factors_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google